Cantor Fitzgerald Downgrades CRISPR Therapeutics (CRSP) to Neutral
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.55 -0.81%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald analyst Olivia Brayer downgraded CRISPR Therapeutics (NASDAQ: CRSP) from Buy to Neutral.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $44.81 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
